



Sarupria Somani & Associates
Chartered Accountants

Partner : CA Miral Bipinbhai Mehta
B.Com, FCA

**314, 3rd Floor, Imperial Arc,
Opp. Shamaldas College Gate,
Waghawadi Road, Bhavnagar.**
Tel.: 0278-2564366
Mobile : 9909366366
Email : somanibvn@gmail.com

Limited Review Report on standalone un-audited Quarterly and Nine Month ended on 31st December, 2022 financial results of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,
The Board of Directors
Par Drugs and Chemicals Limited

We have reviewed the accompanying statement of standalone un-audited financial results of **Par Drugs and Chemicals Limited** having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter and nine month ended 31st December, 2022 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.

This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on these financial statements based on our review.

We conducted our review of the standalone financial result in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Branches

Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar
Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

SARUPRIA SOMANI & ASSOCIATES
(Firm Regn No. – 010674C)
CHARTERED ACCOUNTANTS


CA MIRAL MEHTA
(Partner)



M.No.145361

Bhavnagar, 10th February, 2023

UDIN - 23145361BGSTNK8612

PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com

Standalone Unaudited Financial Results for the Quarter and Nine Month Ended 31st December, 2022


Statement Of Profit & Loss

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year to Date		Year Ended
		31-12-22	30-09-22	31-12-21	31-12-22	31-12-21	31-03-22
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	2,293.27	2,481.80	1,691.55	7,125.72	5,299.37	7,507.44
II	Other income	3.77	1.58	5.18	20.68	11.69	18.39
III	Total Revenue (I + II)	2,297.04	2,483.37	1,696.73	7,146.40	5,311.06	7,525.83
IV	Expenses:						
	Cost of materials consumed	1,180.70	1,067.89	682.07	3,293.58	1,959.92	2,961.00
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-154.78	-25.42	-32.88	-144.63	-19.39	-78.69
	Employee benefits expense	133.93	103.40	102.57	333.04	287.04	410.13
	Finance costs	2.96	3.00	9.90	10.62	36.07	45.42
	Depreciation and amortization expense	74.25	91.27	77.47	238.53	241.41	328.12
	Other expenses	810.35	745.46	583.77	2,361.27	1,898.51	2,589.53
	Total expenses (IV)	2,047.41	1,985.58	1,422.90	6,092.42	4,403.57	6,255.51
V	Profit / (loss) before exceptional items and tax (III-IV)	249.64	497.79	273.83	1,053.98	907.49	1,270.32
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V - VI)	249.64	497.79	273.83	1,053.98	907.49	1,270.32
VIII	Tax expense:						
	(1) Current tax	62.83	125.28	62.30	265.27	228.40	334.50
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	14.49
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)	186.80	372.51	211.53	788.71	679.09	921.33
X	Profit / (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX + XII)	186.80	372.51	211.53	788.71	679.09	921.33
XIV	Other Comprehensive Income						
A	(i) items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B	(i) items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV)	186.80	372.51	211.53	788.71	679.09	921.33
XVI	Paid up Equity share capital (Face value of Rs. 10 each)	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
XVII	Reserves & Surplus excluding revaluation reserve	5,545.97	5,359.16	4,516.27	5,545.97	4,516.27	4,757.26
XVIII	Earnings per equity share (for discontinued operation)						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised)						
	(1) Basic	1.52	3.03	1.72	6.41	5.52	7.49
	(2) Diluted	1.52	3.03	1.72	6.41	5.52	7.49


For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)



Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

NOTES:

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, -2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and nine month financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th February,2023.
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly and nine month financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 31st December, 2022; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.




8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.

9. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	0
III. Disposed-off during the quarter	-	0
IV. Remaining unresolved at the end of the quarter	-	0

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Jignesh V. Savani
(Director & CEO)
(DIN - 00198203)



Bhavnagar, 10th February, 2023